Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

  • End date
    May 19, 2022
  • participants needed
  • sponsor
    Technische Universität Dresden
Updated on 19 September 2021
ejection fraction
minimal residual disease
residual tumor
neoadjuvant therapy
acute promyelocytic leukemia
blast cells


The proposed trial will address two clinically important questions for younger patients with newly diagnosed acute myeloid leukemia (AML): the optimal dose of daunorubicin in induction therapy and the necessity of a second induction cycle in patients with a good response after the first induction. The primary endpoint is the rate of good responders. Secondary outcomes will be relapse-free survival, overall survival and minimal residual disease kinetics. Patients will be recruited in about 40 treatment centers of the Study Alliance Leukemia study group over a period of 40 months. The results will be of great clinical relevance: First, the study could facilitate the establishment or confirmation of the optimal daunorubicin dose.


In the first part of the trial, patients will be randomly assigned to receive either 90 mg/m2 or 60 mg/m2 daunorubicin in the first induction cycle in addition to standard dosed cytarabine. Assuming a superiority of 90 mg/m2, 436 patients will be recruited. In the second part of the trial, good responders will be randomized to receive either a second or no further induction cycle. Assuming a non-inferiority of the single induction regarding the rate of complete remissions, a number of 360 patients will be included in the second part. Furthermore, in case of a non-inferiority of single versus double induction in good responders, about half of all younger AML patients could be spared a second induction cycle, leading to a reduction in treatment-related mortality, fewer days spent in hospital and improved quality of life.

As a result of the preplanned interim analysis of part I, the sponsor decided to suspend randomization in trial part I and to offer all patients the standard dose of 60 mg/m2 daunorubicin in both induction cycles (part I and II of the trial). Because of this an Amendment was sent to and approved by regulatories and ethics comitee.

The inclusion age was raised to 65 years based on the current German treatment guidelines in which patients up to the age of 65 are considered eligible for intensive induction chemotherapy with DA60 [Onkopedia-Leitlinie 2017].

Condition Acute myeloid leukemia, Acute Myelogenous Leukemia (AML), Acute Myeloid Leukemia
Treatment study part 1 - dose daunorubicin, induction cycles
Clinical Study IdentifierNCT02140242
SponsorTechnische Universität Dresden
Last Modified on19 September 2021


Yes No Not Sure

Inclusion Criteria

Newly diagnosed AML other than acute promyelocytic leukemia (APL) according to WHO criteria, i.e. bone marrow aspirate or biopsy must contain 20% blasts of all nucleated cells or differential blood count must contain 20% blasts. In acute erythroid leukemia, 20% blasts in all non-erythroid bone marrow cells. In AML defined by cytogenetic aberrations, the rate of blasts may be <20%. Secondary AMLs are eligible for inclusion
Age 18- inkl.65 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Adequate liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening
Total bilirubin 1.5 times the upper limit of normal
alanine transaminase (ALT) and aspartate transaminase (AST) 2.5 times upper limit of normal
Creatinine 1.5 times upper limit of normalExclusion Criteria
Adequate cardiac function, i.e. left ventricular ejection fraction (LVEF) of 50% as assessed by transthoracic two-dimensional echocardiography ("M Mode") or multiple gated acquisition scan (MUGA scan)
Signed informed consent
Women must fulfill at least one of the following criteria in order to be eligible for trial inclusion
Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum follicle stimulating hormone (FSH) > 40 U/ml)
Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy
Continuous and correct application of a contraception method with a Pearl Index of <1% (e.g. implants, depots, oral contraceptives, intrauterine device - IUD)
Sexual abstinence
Vasectomy of the sexual partner

Exclusion Criteria

Patients who are not eligible for standard chemotherapy as assessed by the treating physician
Central nervous system manifestation of AML
Cardiac disease: i.e. heart failure New York Heart Association (NYHA) III or IV; unstable coronary artery disease (MI more than 6 months prior to study entry is permitted); serious cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
Patients undergoing renal dialysis
Chronic pulmonary disease with clinical relevant hypoxia
Known HIV or Hepatitis infection
Uncontrolled active infection
Medical conditions other than AML with an estimated life expectancy below 6 months
Previous treatment of AML except hydroxyurea up to 5 days
Relapsed or primary refractory AML
Acute promyelocytic leukemia
Previous anthracycline-containing chemotherapy
Treatment with any known non-marketed drug substance or experimental therapy within 4 weeks prior to enrollment
Incapability of understanding purpose and possible consequences of the trial
Pregnant or breastfeeding women
Evidence suggesting that the patient is not likely to follow the study protocol (e.g. lacking compliance)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note